Why biopharma needs asset-light manufacturing models now
Asset-light manufacturing lets biopharma build more agile, modular and technology-enabled supply chains.
Asset-light models help biopharma adapt to a new era of globalization.
Finding the path forward
Companies face two broad paths.
Path 1: regionalization and onshoring
Building capacity closer to markets for resilience and policy reasons.
Path 2: continued divestment and externalization
Relying more on contract manufacturers and partners.
Three underlying drivers
Cost pressure, technology change and the need for flexibility.
One way forward: an asset-light future
Own what differentiates; partner for the rest.
Value areas and key considerations
Quality, supply security and intellectual property.
Value levers
Lower capital intensity, faster scale-up and access to new technology.
Types of asset-light transactions
Site sales with supply agreements, joint ventures and long-term partnerships.
Summary
Asset-light models can make biopharma manufacturing more agile and efficient.
Related articles
How biopharma can get the right mix of people and technology for launch success
Biopharma companies need an end-to-end, AI-enabled launch strategy to succeed in a challenging market.
How life sciences legal teams prepare for a technology-driven future
Emerging health technology creates new data flows and new legal and privacy questions for life sciences companies.
How next-generation CRM will reshape the life sciences commercial model
Customer relationship management in life sciences must move from static maps to real-time navigation.